8-K: Charlottes Web Reports Q2 2026: Balance Sheet Strengthened, Regulatory Hopes Rise

Charlottes Web Holdings, Inc. announced second quarter 2026 results, highlighting a strengthened balance sheet through debenture conversion, expanded gross margins, and reduced operating cash use, alongside positive federal hemp policy developments.

Summary

• Charlottes Web Holdings, Inc. reported financial results for the second quarter ended June 30, 2026.
• The company completed a recapitalization transaction, converting C$75.3 million of convertible debentures and receiving a $10 million equity investment from BT DE Investments Inc. (BAT), a subsidiary of British American Tobacco.
• This transaction eliminated the company's largest liability, restored positive shareholders' equity, and increased cash reserves.
• Gross margin improved to 47.5% from 46.8% year-over-year, driven by a shift in channel and product mix and the transition to in-house gummy production.
• Operating cash use decreased to $0.9 million in Q2 2026 from $2.8 million in Q1 2026, with net cash used in operating activities for the six months at $3.7 million.
• Revenue for Q2 2026 was $10.9 million, a decrease of 15.2% compared to $12.8 million in Q2 2025, attributed to a strategic exit from the retail landscape.
• Significant federal hemp policy reform movements occurred, including legislative proposals to revise or delay a federal hemp product ban and Senate action to postpone its enactment.
• The company is advancing its healthcare strategy, engaging in pilot programs with Accountable Care Organizations (ACOs) and continuing the clinical development of AJA001 Oral Solution through DeFloria, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a cautiously optimistic development, primarily driven by significant balance sheet improvements and positive regulatory shifts, despite ongoing revenue challenges.

Positives

• Elimination of $57 million in liabilities through the conversion of the convertible debenture, significantly strengthening the balance sheet.
• Restoration of positive shareholders' equity, increasing to $56.1 million from a deficit of $2.0 million.
• Gross margin expansion to 47.5% in Q2 2026, up from 46.8% in Q2 2025, indicating improved profitability on sales.
• Reduction in operating cash use to $0.9 million in Q2 2026, a significant improvement from $2.8 million in Q1 2026.
• Net cash used in operating activities for the six months improved by approximately 45% year-over-year, down to $3.7 million from $6.8 million.
• Increased cash and cash equivalents to $14.0 million as of June 30, 2026.
• Positive developments in federal hemp policy, including legislative proposals and Senate action to postpone a ban, creating a more favorable regulatory outlook.
• Advancement of the DeFloria clinical program for AJA001 Oral Solution, with a focus on autism spectrum disorder and rare pediatric neurological indications.

Negatives

• Consolidated net revenue decreased by 15.2% to $10.9 million in Q2 2026 compared to $12.8 million in Q2 2025.
• Revenue for the six months ended June 30, 2026, decreased by 12.2% to $22.0 million compared to $25.1 million in the prior year period.
• Net loss for Q2 2026 was $4.1 million, compared to a net loss of $6.3 million in Q2 2025, though the loss per share improved slightly to $(0.02) from $(0.04).
• California enacted SB 378 and AB 8, materially restricting the sale of hemp-derived CBD products and effectively eliminating full-spectrum hemp products from the market, which represents approximately 10% of revenue.
• Initiation of the Phase 2 trial for DeFloria's AJA001 remains subject to securing the necessary resources to fund it.
• The company incurred a non-cash loss of $4.2 million from the extinguishment of debt in the second quarter.

Risks

• The outcome of federal legislative processes regarding hemp product regulation remains uncertain, and any final policy solution could have a material impact on the Company.
• California's new regulations (SB 378 and AB 8) materially restrict the sale of hemp-derived CBD products, potentially impacting revenue from this key market.
• Initiation of the Phase 2 clinical trial for DeFloria's AJA001 is contingent on securing the required funding.
• The Company cannot predict whether the proposed hemp extension will be enacted into law or the form any final policy solution will take.
• The market for the Company's products, regulatory changes, and competition are ongoing risks.
• Supply and distribution chains, product acceptance, and economic and political considerations pose potential challenges.

Future Outlook

Management expects continued improvement in gross margin towards a target range of approximately 50%, supported by a shift away from lower-margin sales channels and scaling in-house manufacturing. SG&A expenses are expected to remain in a normalized range of approximately $10 million per quarter. The company anticipates continued improvement in its cash flow profile due to debt elimination, reduced operating expenses, and expected gross margin improvements. The company expects DeFloria to provide further detail on its expanded development strategy as programs advance.

Management Comments

• "The second quarter fundamentally changed Charlotte's Web's financial position. We completed the recapitalization, strengthened the balance sheet, and positioned the Company to pursue our healthcare strategy and federal regulatory priorities from a position of strength," said Bill Morachnick, Chief Executive Officer.
• "Our near-term revenue reflects the channel decisions we made last September to largely exit the retail landscape, delivering the margin and cash flow improvements coming through the quarter. But the bigger Q2 story has been Federal hemp policy movements, which are continuing."
• "The Administration, CMS and bipartisan members of Congress are aligning to protect non-intoxicating full-spectrum hemp products, drawing the same distinction we have argued for years: naturally occurring full-spectrum hemp is not the same thing as synthetic intoxicants, and policy should stop treating them alike."
• "We intend to keep making that case, and to keep educating the public about what full-spectrum hemp actually is and is not. We also continue to advance DeFloria through the FDA Botanical Drug Pathway, extending our botanical science into regulated medicine."
• "The balance sheet is in a fundamentally different position than it was ninety days ago," said Erika Lind, Chief Financial Officer. "We eliminated $57 million of liabilities since year-end, restored positive shareholders' equity, and ended the quarter with $14.0 million in cash."

Industry Context

StockSavvy.ai notes that Charlottes Web's Q2 2026 results are occurring amidst significant federal and state-level regulatory flux for hemp-derived products. The company's strategic focus on distinguishing full-spectrum hemp from synthetic cannabinoids and pursuing a healthcare strategy aligns with broader industry efforts to establish clearer regulatory pathways and integrate cannabinoid products into mainstream wellness and medicine.

Management Changes

Related Party Transactions

• The company's in-house gummy production supports further gross margin improvement as production volumes scale, and this includes related-party supply to DeFloria recorded at zero gross margin.

Stakeholder Impact

• Shareholders benefit from the strengthened balance sheet, elimination of significant liabilities, and restoration of positive equity.
• Customers may see continued product innovation and potential for improved access to hemp-derived wellness products, pending regulatory developments.
• Healthcare providers and patients may benefit from the advancement of DeFloria's clinical programs and potential integration of CBD into value-based care models.

Next Steps

• Continue to advance DeFloria through the FDA Botanical Drug Pathway.
• Launch reformulated products intended to support the California market.
• Evaluate channel and advocacy options to protect California consumers and push policy solutions.
• Engage Accountable Care Organizations (ACOs) to launch pilot programs evaluating the role of CBD within value-based care models.
• Provide further detail on DeFloria's expanded development strategy as programs advance.
• Host a second quarter earnings review and corporate update call and webcast later in August 2026.

Key Dates

Recommendation

The company has made significant progress in strengthening its balance sheet and navigating a complex regulatory environment, which are positive developments. However, the continued decline in revenue and ongoing net losses suggest that while the situation is improving, it has not yet reached a point of sustained growth or profitability. Therefore, a 'hold' recommendation reflects a balanced view of the recent improvements against the remaining challenges.

Keywords

hemp, CBD, cannabidiol, regulatory framework, financial results, balance sheet, gross margin, healthcare strategy